BRCA1-directed, enhanced and aberrant homologous recombination: Mechanism and potential treatment strategies

Cell Cycle

Volumn 11, Issue 4, 2012, Pages 687-694

  Dever, Seth M ^a   White, E Railey ^b   Hartman, Matthew C T ^a,b   Valerie, Kristoffer ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

BRCT; DNA repair; Peptide; Radiation; RING; Ubiquitylation

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; CISPLATIN; OXALIPLATIN; TRANSPLATIN; UBIQUITIN PROTEIN LIGASE E3; ZINC FINGER PROTEIN;

BINDING AFFINITY; BREAST CANCER; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG STRUCTURE; ENZYME ACTIVITY; GENE MUTATION; IC 50; OVARY CANCER; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

EID: 84857468940     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.4.19212     Document Type: Review

References (80)

1. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 2009; 4:461-87; PMID:18954285; http://dx.doi.org/10.1146/ annurev.pathol.3.121806.151422.
2. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71; PMID:7545954; http://dx.doi.org/10.1126/ science.7545954.
3. Huen MSY, Sy SMH, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010; 11:138-48; PMID:20029420; http://dx.doi.org/10.1038/nrm2831.
4. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010; 11:196- 207; PMID:20177395; http://dx.doi.org/10.1038/ nrm2851.
5. Messick TE, Greenberg RA. The ubiquitin landscape at DNA double-strand breaks. J Cell Biol 2009; 187:319-26; PMID:19948475; http://dx.doi. org/10.1083/jcb.200908074.
6. Yu X, Fu S, Lai M, Baer R, Chen J. BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev 2006; 20:1721-6; PMID:16818604; http://dx.doi.org/10.1101/gad.1431006.
7. Sobhian B, Shao G, Lilli DR, Culhane AC, Moreau LA, Xia B, et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007; 316:1198-202; PMID:17525341; http:// dx.doi.org/10.1126/science.1139516.
8. Kim H, Chen J, Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007; 316:1202-5; PMID:17525342; http://dx.doi.org/10.1126/science. 1139621.
9. Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, Gygi SP, et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007; 316:1194- 8; PMID:17525340; http://dx.doi.org/10.1126/ science. 1139476.
10. Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, Nederlof PM, et al. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 2011; 477:179-84; PMID:21901007; http:// dx.doi.org/10.1038/nature10371.
11. Reid LJ, Shakya R, Modi AP, Lokshin M, Cheng JT, Jasin M, et al. E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks. Proc Natl Acad Sci USA 2008; 105:20876- 81; PMID:19088202; http://dx.doi.org/10.1073/ pnas.0811203106.
12. Shakya R, Reid LJ, Reczek CR, Cole F, Egli D, Lin CS, et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 2011; 334:525-8; PMID:22034435; http://dx.doi.org/10.1126/ science.1209909.
13. Greenberg RA. Cancer. BRCA1, everything but the RING? Science 2011; 334:459-60; PMID:22034420; http://dx.doi.org/10.1126/science.1214057.
14. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho-protein binding domain. Science 2003; 302:639-42; PMID:14576433; http:// dx.doi.org/10.1126/science.1088753.
15. Manke IA, Lowery DM, Nguyen A, Yaffe MB. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 2003; 302:636- 9; PMID:14576432; http://dx.doi.org/10.1126/science. 1088877.
16. Liu Z, Wu J, Yu X. CCDC98 targets BRCA1 to DNA damage sites. Nat Struct Mol Biol 2007; 14:716- 20; PMID:17643121; http://dx.doi.org/10.1038/ nsmb1279.
17. Yan J, Kim YS, Yang XP, Li LP, Liao G, Xia F, et al. The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response. Cancer Res 2007; 67:6647-56; PMID:17621610; http://dx.doi. org/10.1158/0008-5472.CAN-07-0924.
18. Kim H, Huang J, Chen J. CCDC98 is a BRCA1- BRCT domain-binding protein involved in the DNA damage response. Nat Struct Mol Biol 2007; 14:710- 5; PMID:17643122; http://dx.doi.org/10.1038/ nsmb1277.
19. Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, Bartek J, et al. Human CtIP promotes DNA end resection. Nature 2007; 450:509-14; PMID:17965729; http://dx.doi.org/10.1038/nature06337.
20. Cantor S, Drapkin R, Zhang F, Lin Y, Han J, Pamidi S, et al. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci USA 2004; 101:2357-62; PMID:14983014; http://dx.doi. org/10.1073/pnas.0308717101.
21. Kumaraswamy E, Shiekhattar R. Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase. Mol Cell Biol 2007; 27:6733-41; PMID:17664283; http://dx.doi.org/10.1128/MCB.00961-07.
22. Harris JL, Khanna KK. BRCA1 A-complex fine tunes repair functions of BRCA1. Aging (Albany NY) 2011; 3:461-3; PMID:21805697.
23. Guirouilh-Barbat JK, Wilhelm T, Lopez BS. AKT1/ BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers. Oncotarget 2010; 1:691-9; PMID:21321378.
24. Hu Y, Scully R, Sobhian B, Xie A, Shestakova E, Livingston DM. RAP80-directed tuning of BRCA1 homologous recombination function at ionizing radiation-induced nuclear foci. Genes Dev 2011; 25:685- 700; PMID:21406551; http://dx.doi.org/10.1101/ gad.2011011.
25. Coleman KA, Greenberg RA. The BRCA1-RAP80 complex regulates DNA repair mechanism utilization by restricting end resection. J Biol Chem 2011; 286:13669-80; PMID:21335604; http://dx.doi. org/10.1074/jbc.M110.213728.
26. Dever SM, Golding SE, Rosenberg E, Adams BR, Idowu MO, Quillin JM, et al. Mutations in the BRCT binding site of BRCA1 result in hyper-recombination. Aging (Albany NY) 2011; 3:515-32; PMID:21666281.
27. Nimonkar AV, Genschel J, Kinoshita E, Polaczek P, Campbell JL, Wyman C, et al. BLM-DNA2- RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair. Genes Dev 2011; 25:350-62; PMID:21325134; http://dx.doi.org/10.1101/ gad.2003811.
28. Dellaire G, Bazett-Jones DP. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 2004; 26:963-77; PMID:15351967; http:// dx.doi.org/10.1002/bies.20089.
29. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 2007; 8:1006- 16; PMID:17928811; http://dx.doi.org/10.1038/ nrm2277.
30. Praefcke GJ, Hofmann K, Dohmen RJ. SUMO playing tag with ubiquitin. Trends Biochem Sci 2012; PMID:22018829; http://dx.doi.org/10.1016/j. tibs.2011.09.002.
31. Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM, Jackson SP. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 2009; 462:935- 9; PMID:20016603; http://dx.doi.org/10.1038/ nature08657.
32. Morris JR, Boutell C, Keppler M, Densham R, Weekes D, Alamshah A, et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009; 462:886-90; PMID:20016594; http://dx.doi.org/10.1038/ nature08593.
33. Boichuk S, Hu L, Makielski K, Pandolfi PP, Gjoerup OV. Functional connection between Rad51 and PML in homology-directed repair. PLoS One 2011; 6:25814; PMID:21998700; http://dx.doi. org/10.1371/journal.pone.0025814.
34. Shao G, Lilli DR, Patterson-Fortin J, Coleman KA, Morrissey DE, Greenberg RA. The Rap80-BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8-Ubc13-dependent ubiquitination events at DNA double strand breaks. Proc Natl Acad Sci USA 2009; 106:3166-71; PMID:19202061; http://dx.doi. org/10.1073/pnas.0807485106.
35. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97:2187- 95; PMID:12712470; http://dx.doi.org/10.1002/ cncr.11310.
36. Price M, Monteiro AN. Fine tuning chemotherapy to match BRCA1 status. Biochem Pharmacol 2010; 80:647-53; PMID:20510205; http://dx.doi. org/10.1016/j.bcp.2010.05.015.
37. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26:5530- 6; PMID:18955455; http://dx.doi.org/10.1200/ JCO.2008.16.1703.
38. Hawtin RE, Stockett DE, Wong OK, Lundin C, Helleday T, Fox JA. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget 2010; 1:606- 19; PMID:21317456.
39. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; http:// dx.doi.org/10.1038/nature03445.
40. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui- Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-34; PMID:19553641; http://dx.doi.org/10.1056/ NEJMoa0900212.
41. Saha T, Smulson M, Rosen EM. BRCA1 regulation of base excision repair pathway. Cell Cycle 2010; 9:2471-2; PMID:20581465.
42. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011; 10:1192- 9; PMID:21487248; http://dx.doi.org/10. 4161/ cc.10.8.15273.
43. Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 1999; 4:1093-9; PMID:10635334; http:// dx.doi.org/10.1016/S1097-2765(00)80238-5.
44. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004; 3:301- 17; PMID:15060526; http://dx.doi.org/10.1038/ nrd1343.
45. Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res 2007; 13:7264-70; PMID:18094406; http:// dx.doi.org/10.1158/1078-0432.CCR-07- 2184.
46. Shiozaki EN, Gu L, Yan N, Shi Y. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. Mol Cell 2004; 14:405-12; PMID:15125843; http://dx.doi. org/10.1016/S1097-2765(04)00238-2.
47. Clapperton JA, Manke IA, Lowery DM, Ho T, Haire LF, Yaffe MB, et al. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 2004; 11:512-8; PMID:15133502; http:// dx.doi.org/10.1038/nsmb775.
48. Williams RS, Lee MS, Hau DD, Glover JN. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol 2004; 11:519-25; PMID:15133503; http://dx.doi. org/10.1038/nsmb776.
49. Brzovic PS, Rajagopal P, Hoyt DW, King MC, Klevit RE. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol 2001; 8:833- 7; PMID:11573085; http://dx.doi.org/10.1038/ nsb1001-833.
50. Atipairin A, Canyuk B, Ratanaphan A. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs. Breast Cancer Res Treat 2011; 126:203- 9; PMID:20878461; http://dx.doi.org/10.1007/ s10549-010-1182-7.
51. Yuan Z, Kumar EA, Campbell SJ, Palermo NY, Kizhake S, Mark Glover JN, et al. Exploiting the P-1 pocket of BRCT domains toward a structure guided inhibitor design. ACS Med Chem Lett 2011; 2:764- 7; PMID:22046493; http://dx.doi.org/10.1021/ ml200147a.
52. Brzovic PS, Keeffe JR, Nishikawa H, Miyamoto K, Fox D, 3rd, Fukuda M, et al. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci USA 2003; 100:5646-51; PMID:12732733; http://dx.doi. org/10.1073/pnas.0836054100.
53. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 2001; 98:5134-9; PMID:11320250; http://dx.doi. org/10.1073/pnas.081068398.
54. Jiang J, Yang ES, Jiang G, Nowsheen S, Wang H, Wang T, et al. p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res 2011; 71:5546-57; PMID:21742769; http://dx.doi.org/10.1158/ 0008-5472.CAN-10- 3423.
55. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive á-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91:9770- 4; PMID:7937889; http://dx.doi.org/10.1073/ pnas.91.21.9770.
56. Brzovic PS, Meza JE, King MC, Klevit RE. BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on proteinprotein interactions. J Biol Chem 2001; 276:41399- 406; PMID:11526114; http://dx.doi.org/10.1074/ jbc.M106551200.
57. Almaraz E, de Paula QA, Liu Q, Reibenspies JH, Darensbourg MY, Farrell NP. Thiolate bridging and metal exchange in adducts of a zinc finger model and Pt(II) complexes: biomimetic studies of protein/Pt/ DNA interactions. J Am Chem Soc 2008; 130:6272- 80; PMID:18422317; http://dx.doi.org/10.1021/ ja711254q.
58. Atipairin A, Canyuk B, Ratanaphan A. Cisplatin affects the conformation of apo form, not holo form, of BRCA1 RING finger domain and confers thermal stability. Chem Biodivers 2010; 7:1949- 67; PMID:20730959; http://dx.doi.org/10. 1002/ cbdv.200900308.
59. Leung CC, Glover JN. BRCT domains: easy as one, two, three. Cell Cycle 2011; 10:2461-70; PMID:21734457; http://dx.doi.org/10.4161/ cc.10.15.16312.
60. Rodriguez M, Yu X, Chen J, Songyang Z. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains. J Biol Chem 2003; 278:52914-8; PMID:14578343; http://dx.doi. org/10.1074/jbc.C300407200.
61. Lokesh GL, Muralidhara BK, Negi SS, Natarajan A. Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design. J Am Chem Soc 2007; 129:10658-9; PMID:17685618; http://dx.doi.org/10.1021/ ja0739178.
62. Yuan Z, Kumar EA, Kizhake S, Natarajan A. Structure-activity relationship studies to probe the phosphoprotein binding site on the carboxy terminal domains of the breast cancer susceptibility gene 1. J Med Chem 2011; 54:4264-8; PMID:21574625; http://dx.doi.org/10.1021/jm1016413.
63. Lokesh GL, Rachamallu A, Kumar GDK, Natarajan A. High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1. Anal Biochem 2006; 352:135-41; PMID:16500609; http://dx.doi. org/10.1016/j.ab.2006.01.025.
64. Simeonov A, Yasgar A, Jadhav A, Lokesh GL, Klumpp C, Michael S, et al. Dual-f luorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction. Anal Biochem 2008; 375:60-70; PMID:18158907; http://dx.doi. org/10.1016/j.ab.2007.11.039.
65. Hartman MC, Josephson K, Szostak JW. Enzymatic aminoacylation of tRNA with unnatural amino acids. Proc Natl Acad Sci USA 2006; 103:4356- 61; PMID:16537388; http://dx.doi.org/10.1073/ pnas.0509219103.
66. Ma Z, Hartman MC. In vitro selection of unnatural cyclic peptide libraries via mRNA display. Methods Mol Biol 2012; 805:367-90; PMID:22094817; http://dx.doi.org/10.1007/978-1-61779-379-0-21.
67. Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, Weber B, et al. Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res 2000; 60:3299-304; PMID:10866324.
68. Gatei M, Zhou BB, Hobson K, Scott S, Young D, Khanna KK. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J Biol Chem 2001; 276:17276-80; PMID:11278964; http://dx.doi.org/10.1074/jbc. M011681200.
69. Xu B, O'Donnell AH, Kim ST, Kastan MB. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002; 62:4588-91; PMID:12183412.
70. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286:1162-6; PMID:10550055; http:// dx.doi.org/10.1126/science.286. 5442.1162.
71. Sy SM, Huen MS, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 2009; 106:7155-60; PMID:19369211; http://dx.doi. org/10.1073/pnas.0811159106.
72. Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 2009; 19:524-9; PMID:19268590; http://dx.doi.org/10.1016/j. cub.2009.02.018.
73. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006; 22:719-29; PMID:16793542; http://dx.doi. org/10.1016/j.molcel.2006.05.022.
74. Sy SM, Huen MS, Chen J. MRG15 is a novel PALB2-interacting factor involved in homologous recombination. J Biol Chem 2009; 284:21127-31; PMID:19553677; http://dx.doi.org/10.1074/jbc. C109.023937.
75. Kritzer JA. Stapled peptides: Magic bullets in nature's arsenal. Nat Chem Biol 2010; 6:566-7; PMID:20644540; http://dx.doi.org/10.1038/ nchembio.407.
76. Velkova A, Carvalho MA, Johnson JO, Tavtigian SV, Monteiro AN. Identification of Filamin A as a BRCA1-interacting protein required for efficient DNA repair. Cell Cycle 2010; 9:1421-33; PMID:20305393; http://dx.doi.org/10.4161/ cc.9.7.11256.
77. Weaver JM, Edwards PA. Targeted next-generation sequencing for routine clinical screening of mutations. Genome Med 2011; 3:58; PMID:21910929; http://dx.doi.org/10.1186/gm274.
78. Bellosillo B, Tusquets I. Pitfalls and caveats in BRCA sequencing. Ultrastruct Pathol 2006; 30:229-35; PMID:16825125; http://dx.doi. org/10.1080/01913120500521281.
79. Rowling PJ, Cook R, Itzhaki LS. Toward classification of BRCA1 missense variants using a biophysical approach. J Biol Chem 2010; 285:20080-7; PMID:20378548; http://dx.doi.org/10.1074/jbc. M109.088922.
80. Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res 2010; 70:4880-90; PMID:20516115; http:// dx.doi.org/10.1158/0008-5472.CAN-09-4563.